TW589303B - Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists - Google Patents

Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists Download PDF

Info

Publication number
TW589303B
TW589303B TW090123001A TW90123001A TW589303B TW 589303 B TW589303 B TW 589303B TW 090123001 A TW090123001 A TW 090123001A TW 90123001 A TW90123001 A TW 90123001A TW 589303 B TW589303 B TW 589303B
Authority
TW
Taiwan
Prior art keywords
scope
patent application
cns
item
national standard
Prior art date
Application number
TW090123001A
Other languages
English (en)
Chinese (zh)
Inventor
Neng-Yang Shih
Daniel M Solomon
John J Piwinski
Andrew T Lupo Jr
Michael J Green
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of TW589303B publication Critical patent/TW589303B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW090123001A 2000-09-20 2001-09-19 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists TW589303B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23405300P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
TW589303B true TW589303B (en) 2004-06-01

Family

ID=22879692

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090123001A TW589303B (en) 2000-09-20 2001-09-19 Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists

Country Status (15)

Country Link
US (1) US6506756B2 (enExample)
EP (1) EP1318994B1 (enExample)
JP (1) JP2004509871A (enExample)
CN (1) CN1461303A (enExample)
AR (1) AR030946A1 (enExample)
AT (1) ATE387439T1 (enExample)
AU (1) AU2001292730A1 (enExample)
CA (1) CA2421826C (enExample)
DE (1) DE60133014T2 (enExample)
ES (1) ES2300364T3 (enExample)
HK (1) HK1052179A1 (enExample)
MX (1) MXPA03002448A (enExample)
MY (1) MY117975A (enExample)
TW (1) TW589303B (enExample)
WO (1) WO2002024659A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607862B2 (en) 2001-08-24 2003-08-19 Intel Corporation Damascene extreme ultraviolet lithography alternative phase shift photomask and method of making
RU2323935C2 (ru) * 2002-04-18 2008-05-10 Шеринг Корпорейшн Производные бензимидазола, их применение и фармацевтическая композиция на их основе, обладающая свойствами антагониста рецептора гистамина h3
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1－(4－哌啶基)苯并咪唑酮
US7105505B2 (en) 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
NL1026634C2 (nl) * 2004-07-12 2006-01-16 Willem Jacob Van Der Burg Psychofarmaceutisch preparaat en werkzame stof daarin.
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US9224955B1 (en) * 2014-10-31 2015-12-29 Feng-wen Yen Purifying method for organic optoelectronic material
CN113880808B (zh) * 2020-07-03 2024-12-31 合肥医工医药股份有限公司 一类三唑类化合物、制备方法及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586562B1 (fr) 1985-09-02 1989-03-10 Inst Nat Sante Rech Med Composition pharmaceutique contenant de l'a-methylhistamine
JPH0678315B2 (ja) * 1988-04-28 1994-10-05 シェリング・コーポレーション 新規なベンゾピリド‐ピペリジン、ピペリジリデンおよびピペラジン化合物、組成物、製造法および利用法
GB8916947D0 (en) 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments
EP0448765B1 (de) 1990-03-30 1994-08-17 HEUMANN PHARMA GMBH & CO Verwendung von Guanidinderivaten zur Herstellung eines Arzneimittels mit NPY-antagonistischer Wirkung
GB9115740D0 (en) 1991-07-20 1991-09-04 Smithkline Beecham Plc Medicaments
AU662588B2 (en) 1991-12-18 1995-09-07 Schering Corporation Imidazolyl-alkyl-piperazine and -diazepine derivatives as histamine H3 agonists/antagonists
US5352707A (en) 1992-03-26 1994-10-04 Harbor Branch Oceanographic Institution, Inc. Method for treating airway congestion
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT1019050E (pt) 1997-06-24 2002-09-30 Novo Nordisk As Utilizacao de agonisticos e de antagonisticos de somatostatina para o tratamento de doencas associadas ao olho
US5869479A (en) 1997-08-14 1999-02-09 Schering Corporation Treatment of upper airway allergic responses
WO2000005215A1 (en) 1998-07-24 2000-02-03 Russinsky Limited A process for preparing benzocycloheptapyridin-11-ones

Also Published As

Publication number Publication date
CA2421826C (en) 2009-10-27
AU2001292730A1 (en) 2002-04-02
DE60133014T2 (de) 2009-02-26
ES2300364T3 (es) 2008-06-16
US6506756B2 (en) 2003-01-14
EP1318994B1 (en) 2008-02-27
HK1052179A1 (zh) 2003-09-05
WO2002024659A3 (en) 2002-10-24
MXPA03002448A (es) 2003-06-19
ATE387439T1 (de) 2008-03-15
US20020086859A1 (en) 2002-07-04
MY117975A (en) 2004-08-30
DE60133014D1 (de) 2008-04-10
JP2004509871A (ja) 2004-04-02
WO2002024659A2 (en) 2002-03-28
CN1461303A (zh) 2003-12-10
CA2421826A1 (en) 2002-03-28
AR030946A1 (es) 2003-09-03
EP1318994A2 (en) 2003-06-18

Similar Documents

Publication Publication Date Title
JP5622568B2 (ja) ベンズアミドｍＧｌｕＲ５の正のアロステリック調節因子ならびにその作製および使用方法
US8580957B2 (en) Thetrahydroquinolines derivatives as bromodomain inhibitors
US6825189B1 (en) Certain heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
EP1228060A1 (de) Arylalkane, arylalkene und aryl-azaalkane, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CN102482227A (zh) 作为γ分泌酶调节剂的取代的三唑和咪唑衍生物
JP2010531835A (ja) Ｃｃｒ２受容体アンタゴニストとしてのイミダゾール誘導体
DE69819903T2 (de) Bicyclische verbindungen als liganden der 5-ht1 rezeptoren
CA2242579A1 (en) Benzimidzolyl neuropeptide y receptor antagonists
JP2006519802A (ja) イミダゾール−４−イル−エチニル−ピリジン誘導体
WO2007121687A1 (en) 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20020045618A1 (en) Heteroaryl diazacycloalkanes, their preparation and use
WO2014001279A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
EP1318996B1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
EP1318994B1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
JP2008526895A (ja) ヒスタミンｈ３アンタゴニストとして有用なイミダゾールおよびベンゾイミダゾール誘導体
EP0309425A2 (en) New heterocyclic derivatives
US6518287B2 (en) Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists
EP1318993B1 (en) Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
US6031097A (en) 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
WO2025215225A1 (en) Method for the synthesis of 5-methoxy-2-(2h-1,2,3-triazol-2-yl)benzoic acid, a sodium salt of said acid as a synthetic intermediate, and use of the acid or the salt thereof in the preparation of daridorexant and certain intermediates in the synthesis thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees